CEO Albert Bourla Kicks Off Pfizer’s 175th Anniversary Celebration
For 175 years, Pfizer has been at the forefront of medical and pharmaceutical breakthroughs that have not only changed patient lives but have impacted the world.
Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe
Recall due to the Potential For Presence of Glass Particulate Matter
FOR IMMEDIATE RELEASE - December 21, 2023 - NEW YORK, NY.
Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter
FOR IMMEDIATE RELEASE - December 21, 2023 - NEW YORK, NY.
Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bleomycin for Injection, USP 15 units Single Dose ONCO-TAIN™ Glass Fliptop Vial, lot BL12206A, to the user level. The recall was initiated due to a confirmed customer report for the presence of glass particulate within a single vial.
Pfizer Accelerates Climate Action through Pan-European Virtual Power Purchase Power Agreements
The impact of climate change on human health is unequivocal. Guided by our company purpose, “Breakthroughs that change patients’ lives”, Pfizer remains committed to reducing our company’s greenhouse gas (GHG) emissions.
Pfizer Launches VaxAssist, to Help Individual’s Assess Respiratory Vaccine Eligibility
As more respiratory vaccinations have become available in recent years, the Centers for Disease Control and Prevention (CDC) continues to provide annual guidelines for common respiratory illnesses—COVID-19, pneumococcal pneumonia, influenza (the flu), and respiratory syncytial virus (RSV)—to help ensure eligible populations are seeking vaccinations, especially during respiratory illness season.
Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment
NEW YORK, December 15, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
ASH 2023: Advancing Potential Breakthroughs for Patients with Hematologic Disorders
This weekend, Pfizer will be joining the hematology/oncology community at the 65th Annual Meeting of the American Society of Hematology (ASH), the premier professional society of clinicians and scientists dedicated to conquering blood diseases.
November Social Media Round-Up—Vaccine Anniversary, Transgender Awareness, and the Corporate Equality Index
Thanksgiving may have kicked off the holiday season, but November was chock full of things to celebrate all month long, including Transgender Awareness Week and Veterans Day.
Pfizer’s 2-in 1 At-Home Test Enables Convenient Testing for both COVID-19 and the Flu
When we think of winter, hot chocolate, cozy fireplaces, and catching up with friends and family often come to mind. But 'tis also peak respiratory virus season, with viruses like the flu and COVID-19 making the rounds at holiday parties and gatherings everywhere.
Listen Now: Award-Winning ‘Science Will Win’ Podcast Explores Antimicrobial Resistance
This week, season three of Pfizer’s signature Science Will Win podcast—which debuted as one of the top 1% podcasts globally—returns with a look at antimicrobial resistance (AMR), one of healthcare’s greatest threats, and the innovative ways doctors and scientists are leveraging emerging technology to fight it.